<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05084508</url>
  </required_header>
  <id_info>
    <org_study_id>217212</org_study_id>
    <nct_id>NCT05084508</nct_id>
  </id_info>
  <brief_title>A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age</brief_title>
  <official_title>A Phase II, Observer-blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of a Varicella Vaccine at Various Potencies Compared With Varivax, as a First Dose, Administered in Healthy Children in Their Second Year of Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IQVIA, USA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess immune response and safety of various potencies of an&#xD;
      investigational chickenpox vaccine given to healthy children 12 to 15 months of age.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 4, 2022</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 9, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Observer-blind study. Recipients and study evaluators will be unaware of vaccine administered.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Concentrations of anti-glycoprotein E (gE) antibodies</measure>
    <time_frame>At Day 43</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with seroresponse to gE</measure>
    <time_frame>At Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants reporting solicited administration site events</measure>
    <time_frame>During the 4-day period after the administration of study interventions (administered at Day 1)</time_frame>
    <description>Solicited administration site events include injection site redness, pain and swelling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants reporting solicited systemic events</measure>
    <time_frame>During the 43-day period after the administration of study interventions (administered at Day 1)</time_frame>
    <description>Solicited systemic events include fever and varicellalike rash after the administration of all vaccines for each group. Fever is defined as temperature greater than or equal to (≥)38.0 degrees Celsius (°C) (100.4 degrees Fahrenheit [°F]) by any route (the preferred location for measuring temperature is the axilla). A typical varicella-like rash manifests as a rash/lesions that may appear within several weeks after the varicella vaccination. Lesions may contain spots, bumps, blisters, or crusts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants reporting unsolicited adverse events</measure>
    <time_frame>During the 43 days-period after the administration of study interventions (administrated at Day 1)</time_frame>
    <description>Unsolicited adverse events (AEs) include any AE reported in addition to solicited events during the study, or any &quot;solicited&quot; symptoms with onset outside of the specified period of follow-up for solicited symptoms, are assessed for each group after the administration of all vaccines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants reporting serious adverse events (SAEs)</measure>
    <time_frame>Throughout the entire study period (From Day 1 to Day 181)</time_frame>
    <description>A SAE is an AE which is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or other situations that are considered serious per medical or scientific judgment.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Chickenpox</condition>
  <arm_group>
    <arm_group_label>VNS_Low Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy children aged 12 to 15 months of age receive 1 dose of an investigational varicella vaccine (VNS) of low potency, 1 dose of a measles, mumps, and rubella vaccine, 1 dose of a hepatitis A vaccine, and 1 dose of a 13-valent pneumococcal conjugate vaccine on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VNS_Med Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy children aged 12 to 15 months of age receive 1 dose of an investigational varicella vaccine (VNS) of medium potency, 1 dose of a measles, mumps, and rubella vaccine, 1 dose of a hepatitis A vaccine, and 1 dose of a 13-valent pneumococcal conjugate vaccine on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VNS_High Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy children aged 12 to 15 months of age receive 1 dose of an investigational varicella vaccine (VNS) of high potency, 1 dose of a measles, mumps, and rubella vaccine, 1 dose of a hepatitis A vaccine, and 1 dose a 13-valent pneumococcal conjugate vaccine on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VV_Lot1 Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy children aged 12 to 15 months of age receive 1 dose of a marketed varicella vaccine (VV) of Lot 1, 1 dose of a measles, mumps, and rubella vaccine, 1 dose of a hepatitis A vaccine, and a 1 dose of a 13-valent pneumococcal conjugate vaccine on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VV_Lot2 Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy children aged 12 to 15 months of age receive 1 dose of a marketed varicella vaccine (VV) of Lot 2, 1 dose of a measles, mumps, and rubella vaccine, 1 dose of a hepatitis A vaccine, and a 1 dose of a 13-valent pneumococcal conjugate vaccine on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Investigational varicella vaccine low potency</intervention_name>
    <description>1 dose of a low-potency investigational varicella vaccine administered subcutaneously in the upper arm</description>
    <arm_group_label>VNS_Low Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Investigational varicella vaccine medium potency</intervention_name>
    <description>1 dose of a medium-potency investigational varicella vaccine administered subcutaneously in the upper arm</description>
    <arm_group_label>VNS_High Group</arm_group_label>
    <arm_group_label>VNS_Low Group</arm_group_label>
    <arm_group_label>VNS_Med Group</arm_group_label>
    <arm_group_label>VV_Lot1 Group</arm_group_label>
    <arm_group_label>VV_Lot2 Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Investigational varicella vaccine high potency</intervention_name>
    <description>1 dose of a high-potency investigational varicella vaccine administered subcutaneously in the upper arm</description>
    <arm_group_label>VNS_High Group</arm_group_label>
    <arm_group_label>VNS_Low Group</arm_group_label>
    <arm_group_label>VNS_Med Group</arm_group_label>
    <arm_group_label>VV_Lot1 Group</arm_group_label>
    <arm_group_label>VV_Lot2 Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Marketed varicella vaccine Lot 1</intervention_name>
    <description>1 dose of a marketed varicella vaccine of Lot 1 administered subcutaneously in the upper arm</description>
    <arm_group_label>VNS_High Group</arm_group_label>
    <arm_group_label>VNS_Low Group</arm_group_label>
    <arm_group_label>VNS_Med Group</arm_group_label>
    <arm_group_label>VV_Lot1 Group</arm_group_label>
    <arm_group_label>VV_Lot2 Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Marketed varicella vaccine Lot 2</intervention_name>
    <description>1 dose of a marketed varicella vaccine of Lot 2 administered subcutaneously in the upper arm</description>
    <arm_group_label>VNS_High Group</arm_group_label>
    <arm_group_label>VNS_Low Group</arm_group_label>
    <arm_group_label>VNS_Med Group</arm_group_label>
    <arm_group_label>VV_Lot1 Group</arm_group_label>
    <arm_group_label>VV_Lot2 Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Measles, mumps, and rubella vaccine</intervention_name>
    <description>1 dose of a measles, mumps, and rubella vaccine administered subcutaneously in the upper arm</description>
    <arm_group_label>VNS_High Group</arm_group_label>
    <arm_group_label>VNS_Low Group</arm_group_label>
    <arm_group_label>VNS_Med Group</arm_group_label>
    <arm_group_label>VV_Lot1 Group</arm_group_label>
    <arm_group_label>VV_Lot2 Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hepatitis A vaccine</intervention_name>
    <description>1 dose of a hepatitis A vaccine administered intramuscularly in the anterolateral thigh</description>
    <arm_group_label>VNS_High Group</arm_group_label>
    <arm_group_label>VNS_Low Group</arm_group_label>
    <arm_group_label>VNS_Med Group</arm_group_label>
    <arm_group_label>VV_Lot1 Group</arm_group_label>
    <arm_group_label>VV_Lot2 Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-valent pneumococcal conjugate vaccine</intervention_name>
    <description>1 dose of a 13-valent pneumococcal conjugate vaccine administered intramuscularly in the anterolateral thigh</description>
    <arm_group_label>VNS_High Group</arm_group_label>
    <arm_group_label>VNS_Low Group</arm_group_label>
    <arm_group_label>VNS_Med Group</arm_group_label>
    <arm_group_label>VV_Lot1 Group</arm_group_label>
    <arm_group_label>VV_Lot2 Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy participants as established by medical history and clinical examination before&#xD;
             entering into the study.&#xD;
&#xD;
          -  A male or female between, and including, 12 and 15 months of age (i.e., from his/her 1&#xD;
             year birthday until the day before age of 16 months) at the time of the administration&#xD;
             of the study interventions.&#xD;
&#xD;
          -  Written informed consent obtained from the parent(s)/legally authorized&#xD;
             representative(s) of the participant prior to performance of any study-specific&#xD;
             procedure.&#xD;
&#xD;
          -  Participants' parent(s)/legally authorized representative(s), who, in the opinion of&#xD;
             the investigator, can and will comply, with the requirements of the protocol (e.g.,&#xD;
             completion of Electronic Diaries, return for follow-up visits).&#xD;
&#xD;
          -  Participants who previously received the primary series of pneumococcal conjugate&#xD;
             vaccine in their first year of life with the last dose at least 60 days prior to study&#xD;
             entry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Medical Conditions&#xD;
&#xD;
          -  History of any reaction or hypersensitivity likely to be exacerbated by any component&#xD;
             of the study interventions including hypersensitivity to neomycin or gelatin.&#xD;
&#xD;
          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on&#xD;
             medical history and physical examination (no laboratory testing required).&#xD;
&#xD;
          -  Hypersensitivity to latex.&#xD;
&#xD;
          -  Major congenital defects, as assessed by the investigator.&#xD;
&#xD;
          -  History of varicella.&#xD;
&#xD;
          -  Recurrent history of or uncontrolled neurological disorders or seizures.&#xD;
&#xD;
          -  Participant with history of SARS-CoV-2 infection who is still symptomatic.&#xD;
&#xD;
          -  Any other clinical condition that, in the opinion of the investigator, might pose&#xD;
             additional risk to the participant due to participation in the study.&#xD;
&#xD;
        Prior and Concomitant Therapy&#xD;
&#xD;
          -  Use of any investigational or non-registered product (drug, vaccine or medical device)&#xD;
             other than the study interventions during the period beginning 30 days before the dose&#xD;
             of study interventions (Day -29 to Day 1), or planned use during the study period.&#xD;
&#xD;
          -  Chronic administration (defined as more than 14 days in total) of immunosuppressants,&#xD;
             or other immune-modifying drugs during the period starting 90 days prior to the study&#xD;
             interventions administration. For corticosteroids, this will mean prednisone&#xD;
             equivalent ≥ 0.5 mg/kg/day or 20 mg/day whichever is the maximum dose for pediatric&#xD;
             participants, or equivalent. Inhaled and topical steroids are allowed.&#xD;
&#xD;
          -  Administration of immunoglobulins and/or any blood products or plasma derivatives&#xD;
             during the period starting 180 days before the dose of study interventions or planned&#xD;
             administration during the study period.&#xD;
&#xD;
          -  Administration of long-acting immune-modifying drugs at any time during the study&#xD;
             period (e.g., infliximab).&#xD;
&#xD;
          -  Previous vaccination against measles, mumps, rubella, hepatitis A, and/or varicella&#xD;
             virus.&#xD;
&#xD;
        Medical Conditions&#xD;
&#xD;
          -  History of any reaction or hypersensitivity likely to be exacerbated by any component&#xD;
             of the study interventions including hypersensitivity to neomycin or gelatin.&#xD;
&#xD;
          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on&#xD;
             medical history and physical examination (no laboratory testing required).&#xD;
&#xD;
          -  Hypersensitivity to latex.&#xD;
&#xD;
          -  Major congenital defects, as assessed by the investigator.&#xD;
&#xD;
          -  History of varicella.&#xD;
&#xD;
          -  Recurrent history of or uncontrolled neurological disorders or seizures.&#xD;
&#xD;
          -  Participant with history of SARS-CoV-2 infection who is still symptomatic.&#xD;
&#xD;
          -  Any other clinical condition that, in the opinion of the investigator, might pose&#xD;
             additional risk to the participant due to participation in the study.&#xD;
&#xD;
        Prior and Concomitant Therapy&#xD;
&#xD;
          -  Use of any investigational or non-registered product (drug, vaccine or medical device)&#xD;
             other than the study interventions during the period beginning 30 days before the dose&#xD;
             of study interventions (Day -29 to Day 1), or planned use during the study period.&#xD;
&#xD;
          -  Chronic administration (defined as more than 14 days in total) of immunosuppressants,&#xD;
             or other immune-modifying drugs during the period starting 90 days prior to the study&#xD;
             interventions administration. For corticosteroids, this will mean prednisone&#xD;
             equivalent ≥ 0.5 mg/kg/day or 20 mg/day whichever is the maximum dose for pediatric&#xD;
             participants, or equivalent. Inhaled and topical steroids are allowed.&#xD;
&#xD;
          -  Administration of immunoglobulins and/or any blood products or plasma derivatives&#xD;
             during the period starting 180 days before the dose of study interventions or planned&#xD;
             administration during the study period.&#xD;
&#xD;
          -  Administration of long-acting immune-modifying drugs at any time during the study&#xD;
             period (e.g., infliximab).&#xD;
&#xD;
          -  Previous vaccination against measles, mumps, rubella, hepatitis A, and/or varicella&#xD;
             virus.&#xD;
&#xD;
          -  Previous administration of a booster dose of any pneumococcal conjugate vaccine.&#xD;
&#xD;
          -  Planned administration/administration of a vaccine not foreseen by the study protocol&#xD;
             in the period starting 30 days before the dose and ending at 43 days after the dose of&#xD;
             study interventions administration* (Visit 3) with the exception of inactivated&#xD;
             influenza (flu) vaccine which may be given at any time during the study and&#xD;
             administered at a different location than the study interventions.&#xD;
&#xD;
          -  Any other age appropriate vaccine may be given starting at Visit 3 and anytime&#xD;
             thereafter.&#xD;
&#xD;
               -  In case of emergency mass vaccination for an unforeseen public health threat&#xD;
                  (e.g., a pandemic) is recommended and/or organized by public health authorities&#xD;
                  outside the routine immunization program, the time period described above can be&#xD;
                  reduced if necessary, for that vaccine, provided it is used according to the&#xD;
                  local governmental recommendations and that the Sponsor is notified accordingly.&#xD;
&#xD;
        Prior/Concurrent Clinical Study Experience&#xD;
&#xD;
        • Concurrently participating in another clinical study, at any time during the study&#xD;
        period, in which the participant has been or will be exposed to an investigational or a non&#xD;
        investigational intervention (drug/invasive medical device).&#xD;
&#xD;
        Other Exclusions&#xD;
&#xD;
          -  Child in care.&#xD;
&#xD;
          -  Any study personnel's immediate dependents, family, or household members.&#xD;
&#xD;
          -  Participants with the following high-risk individuals in their household:&#xD;
&#xD;
               -  Immunocompromised individuals.&#xD;
&#xD;
               -  Pregnant women without documented history of varicella.&#xD;
&#xD;
               -  Newborn infants of mothers without documented history of varicella.&#xD;
&#xD;
               -  Newborn infants born &lt;28 weeks of gestation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>15 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EU GSK Clinical Trials Call Center</last_name>
    <phone>+44 (0) 20 89904466</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 18, 2021</study_first_submitted>
  <study_first_submitted_qc>October 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Varicella</keyword>
  <keyword>Chickenpox</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chickenpox</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

